Analyzing Cost of Revenue: ADMA Biologics, Inc. and Perrigo Company plc

Analyzing Cost of Revenue: ADMA Biologics, Inc. vs. Perrigo Company plc

In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis compares ADMA Biologics, Inc. and Perrigo Company plc over a decade, from 2014 to 2023. ADMA Biologics, a niche player, has seen its cost of revenue skyrocket by over 4,400%, from approximately $3.7 million in 2014 to $169 million in 2023. This growth reflects its aggressive expansion and increased production capabilities. In contrast, Perrigo Company, a global leader, maintains a relatively stable cost of revenue, averaging around $3 billion annually. Despite fluctuations, Perrigo's cost of revenue peaked in 2020 at $3.25 billion, showcasing its resilience amidst market challenges. This comparison highlights the dynamic strategies of a burgeoning biotech firm versus an established pharmaceutical giant.